Healthcare & Life Sciences
Pangea Bio
Pangea Bio is a Healthcare & Life Sciences startup, most recent round Series C+, 2 tracked investors.
series-c-plus
series-c-plus
Stage
2
Investors
About Pangea Bio
Pangea Bio is a startup. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.
Pangea Bio is a clinical-stage biotechnology company developing therapeutics that promote neuroplasticity to treat central nervous system disorders. Its lead candidate OT-003 activates the TrkB receptor pathway and has received Clinical Trial Authorization, and the company is advancing a pipeline of next-generation TrkB activators.
Explore Pangea Bio's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.